PRKD3 and cancer: Even though miR-301b may not be primarily working through PKD3, our findings show that PKD3 inhibition is a promising option for future therapeutics, with CRT0066101 having already been shown to inhibit tumor growth both in vitro and in vivo in several other cancer types (62–65).